Levicept
A UK-based biotech company developing a novel therapies for the treatment of chronic pain.
Levicept's lead candidate is LEVI-04, a first-in-class treatment for chronic pain indications. As of Q1 2024, LEVI-04 is in phase II trials in patients with osteoarthritis of the knee. Top line data is expected to be announced in Q2 2024.
Latest Levicept News & Features
30 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze